8 July 2020 **Sydney, Australia**

Corporate Presentation for the Reach Markets Virtual Event

Sydney, 8 July 2020: Noxopharm (ASX:NOX) provides to shareholders and the market generally the corporate presentation for the Reach Markets "Meet the CEOs" virtual session at 12 noon today.

Noxopharm CEO and Founder, Dr Graham Kelly will provide an updated overview of the Company's oncology program. A short Questions and Answers opportunity will follow.

To register for this free event please visit: Register for Reach Markets Meet the CEO's Event

-ENDS-

About Noxopharm
Noxopharm is a clinical-stage Australian drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in U.S. biotechnology company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:
Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

Forward Looking Statements
This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

Noxopharm Limited (ASX:NOX)

REACH MARKETS " Meet the CEOs ", 8 July 2020

Disclaimer

This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Veyonda®

- NOX is focused on arguably the biggest prize in the pharma industry - a drug that makes the current generation of ***immuno-oncology (I-O)*** anti-cancer drugs work much better
- ***I-O drugs*** came to market 15 years ago to enormous acclaim and promise. However, that promise remains unfulfilled with response rates in a few selected cancers of 10-30% and in most cancers of < 10%
- Despite this limited success, ***I-O drugs*** enjoy sales of US$20 billion p.a. With higher response rates, predicted to be US$200 billion-plus
- Many attempts to develop a drug to increase the response to ***I-O drugs***, but the prize remains unclaimed
- **Noxopharm believes it could have the answer** ***Veyonda®***

Immuno-oncology drugs
Next generation of anti-cancer drugs

- Cancer represents a failure of the body's immune system
- Cancers establish, grow and spread because they protect themselves from immune cells
- ***I-O drugs*** designed to tip balance back in favour of the immune system
- ***I-O drugs*** potentially capable of working in most human cancers, but failure believed associated with ability of tumours to expel immune cells and then prevent their re-entry (**'COLD' tumours**)
- Most human tumours are '**COLD**'.

Converting COLD tumours to HOT tumours
The $multi-billion challenge



Source: Dana-Faber Cancer Institute

Strategy

- Step 1. Confirm in laboratory Veyonda® able to convert human tumours from COLD to HOT ☑
- Step 2. Phase 1 study (25 patients) confirming safety and providing proof-of-concept efficacy signals in cancer type with current poor ***I-O drug*** outcomes ☑
- Step 3. Conduct Phase 2 study (200+ patients) confirming proof-of-concept
- Step 4. Seek industry partner

Prostate cancer: poor responder to *I-O drugs*



Substantial Global Unmet Need[1]

Prostate cancer is the fifth leading cause of death in men worldwide

Responsible for estimated **360,000 deaths** in 2018

Mortality from prostate cancer **estimated to double by 2040**

1.3 million new cases reported worldwide in 2018

Exponential increase in death from prostate cancer with age



Source: 1. Rawla P (2019) World J Oncol 10, 63-89

Veyonda & DARRT



DARRT Explained

DARRT (Direct and Abscopal Response to Radiotherapy)

- DARRT is based on the idea of restoring the ability of the body's immune system to fight the cancer
- Low dose radiotherapy triggers an immune response in the irradiated tumours that contributes to the shrinkage of those tumours
- Adding NOX66 to that treatment is intended to boost that immune response in the irradiated tumours (**direct response**) to the extent that the resulting immune response extends to the bulk of tumours in the rest of the body (**abscopal response**)
- DARRT potentially addresses a large population of patients with no remaining treatment options, typically in considerable pain, poor quality of life, and poor life expectancy

Direct Response



Shrinkage of Irradiated tumor

Complete resolution of Irradiated tumor

Abscopal response



Partial abscopal response

Complete abscopal response

Veyonda®
DARRT-1 Phase 1 study

- 25 men enrolled with late-stage **prostate cancer** and treated
- Metastatic castration-resistant prostate cancer (mCRPC)
- Progressive disease
- No remaining standard treatment options
- Eligible for palliative radiotherapy (RT) for symptomatic relief
- Treatment with low-dose RT (5 days) and Veyonda® (14 days)



Bone scan with metastatic disease

DARRT-1: PSA Response

- Veyonda® in combination with radiation therapy appeared to be **safe and well-tolerated**[1]
- In the 16* patients who were evaluable at 6 months[1]

9 patients lost to follow-up, died or withdrew from study
PSA = prostate specific antigen
1. Noxopharm. Data on file

DARRT-1: Pain Response

- Veyonda® in combination with radiation therapy appeared to be **safe and well-tolerated**[1]
- In the 16* patients who were evaluable at 6 months[1]

Over 30% drop in pain levels in 10/16 patients

4 patients became completely pain-free

9 patients lost to follow-up, died or withdrew from study
PSA = prostate specific antigen
1. Noxopharm. Data on file

DARRT-1: Tumour Response

- In the 15* patients who were evaluable at 6 months[1]
- **The Tumours stopped growing or reduced in size in 10 patients (1 patient achieved a partial response and 9 achieved stable disease at 6 months**
- **Four patients had an abscopal response**

6 months follow-up	First part 400mg, 800mg & 1200mg (reported 12 Nov 2019)	Expansion part 1200mg	Overall All doses (reported 2 Dec 2019)
Overall (RECIST1.1)	N=10	N=5	N=15
Complete response	0	0	0
Partial response	1 (10%)	0	1 (7%)
Stable disease	7 (70%)	2 (40%)	9 (60%)
Progressive disease	2 (20%)	3 (60%)	5 (33%)

1. Noxopharm. Data on file

** 10 patients lost to follow-up, were not measurable, withdrew from study or died (unrelated to treatment)*

DARRT-2: Phase 2 study

- **Objectives:**
  - **The DARRT-2 is designed to provide the data that Commercial Partners are looking for**
  - **It also aims to satisfy the Regulatory Authorities**
- Building on the experience and data of DARRT-1
- Multinational. 2-3 continents. Approx. 200 men
- Medical Advisory Boards established
- Anticipated regulatory submissions late-2020
- Study expected to commence in early-2021

✓ **We are developing the most efficient and impactful study possible**

Advanced prostate cancer: Attracting Significant Pharma Interest

Deal	**Pfizer merger with Medivation (2016)**	**Novartis merger with Endocyte (2018)**	**Novartis acquisition of Advanced Accelerator Applications (2018)**
Price	**US$14 billion**	**US$2.1 billion**	**US$3.9 billion**
Key Assets	**XTANDI®** (enzalutamide), an androgen receptor inhibitor for use in mCRPC which generated approximately $2.2 billion sales in previous 12 months	**^{177}Lu-PSMA-617**, a potential first-in-class radioligand therapy in Phase III development for mCRPC	**^{177}Lu-PSMA-617**, **^{225}AC-PSMA-617 and ^{177}Lu-PSMA-R2** as potential first-in-class radioligand therapies in development for mCRPC

Key metrics

- Market cap A$47M (6 July 2020)
- Share price A$0.22 (6 July 2020)
- Issued cap ~213M shares
- Recently closed A$7.33M net raised
  (rights issue via Canaccord)

News Flow (next 6 -12months)

* Commencement of DARRT-2
* Progress in other clinical programs
* Progress in drug pipeline
* Potential industry collaborations ongoing

NOXOPHARM

For further information

email: info@noxopharm.com
web: www.noxopharm.com

Discover

Develop

Deliver